{"id":"artemether-lumefantrine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Fever"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-3","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL4297927","moleculeType":"Unknown"},"_dailymed":{"setId":"7866ec19-dfac-47d4-a53f-511a12643cbf","title":"COARTEM (ARTEMETHER AND LUMEFANTRINE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, a fast-acting artemisinin derivative, rapidly reduces parasite biomass by generating reactive oxygen species that damage parasite membranes and proteins. Lumefantrine, a slower-acting quinoline-methanol compound, inhibits heme polymerization in the parasite's digestive vacuole, preventing detoxification of toxic heme and leading to parasite death. Together, they provide rapid symptom relief and complete parasite clearance.","oneSentence":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:30.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (in combination therapy)"}]},"trialDetails":[{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT07235033","phase":"PHASE2","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-23","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Uncomplicated Malaria","enrollment":60},{"nctId":"NCT06967519","phase":"PHASE4","title":"OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-18","conditions":"Malaria, Hiv","enrollment":380},{"nctId":"NCT05567016","phase":"NA","title":"CHILD (Child Health and Infection With Low Density) Malaria","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-07-18","conditions":"Malaria,Falciparum, Malaria","enrollment":600},{"nctId":"NCT05842954","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-07","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1720},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":"Malaria Falciparum","enrollment":316},{"nctId":"NCT07358767","phase":"NA","title":"Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women","status":"COMPLETED","sponsor":"Noguchi Memorial Institute for Medical Research","startDate":"2021-07-01","conditions":"Malaria","enrollment":3300},{"nctId":"NCT05757167","phase":"PHASE4","title":"Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-06","conditions":"Malaria,Falciparum, Malaria in Pregnancy, Malaria in Childbirth","enrollment":2500},{"nctId":"NCT04300309","phase":"PHASE2, PHASE3","title":"Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-21","conditions":"Plasmodium Falciparum Malaria","enrollment":28},{"nctId":"NCT04080895","phase":"PHASE1","title":"Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-11-01","conditions":"Pharmacokinetic, Healthy, Drug Combination","enrollment":8},{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":"Severe Malaria","enrollment":254},{"nctId":"NCT04009343","phase":"PHASE2, PHASE3","title":"Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-19","conditions":"Uncomplicated Falciparum Malaria","enrollment":182},{"nctId":"NCT05979207","phase":"PHASE1","title":"Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2023-08-01","conditions":"Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome","enrollment":12},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT05750628","phase":"PHASE2","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-23","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":327},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":"Malaria, Vivax","enrollment":1991},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT06970600","phase":"NA","title":"Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2024-03-07","conditions":"Malaria (Uncomplicated)","enrollment":352},{"nctId":"NCT06516042","phase":"PHASE3","title":"Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"PATH","startDate":"2024-08-21","conditions":"Plasmodium Falciparum, Malaria","enrollment":10350},{"nctId":"NCT05287893","phase":"PHASE1","title":"Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2022-04-04","conditions":"Malaria,Falciparum, Malaria, Malaria Recrudescence","enrollment":10},{"nctId":"NCT03453840","phase":"PHASE4","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-21","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":305},{"nctId":"NCT06347471","phase":"PHASE4","title":"The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy","status":"RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-05-28","conditions":"Falciparum; Malaria","enrollment":120},{"nctId":"NCT04704999","phase":"PHASE4","title":"Southeast Asia Dose Optimization of Tafenoquine","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-22","conditions":"Plasmodium Vivax Malaria","enrollment":700},{"nctId":"NCT05676645","phase":"","title":"Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liverpool","startDate":"2023-03-20","conditions":"Malaria,Falciparum","enrollment":30},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Malaria","enrollment":16},{"nctId":"NCT05764746","phase":"PHASE2, PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":384},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT06076213","phase":"PHASE4","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1260},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04546633","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-16","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":295},{"nctId":"NCT04079621","phase":"PHASE4","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-10-27","conditions":"Malaria, Malaria, Vivax, Malaria,Falciparum","enrollment":27},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT01614964","phase":"PHASE2","title":"Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-08","conditions":"Malaria","enrollment":66},{"nctId":"NCT04280692","phase":"PHASE1, PHASE2","title":"Controlled Human Malaria Infection Transmission Model - Phase A","status":"SUSPENDED","sponsor":"University of Oxford","startDate":"2022-08-22","conditions":"Malaria,Falciparum","enrollment":44},{"nctId":"NCT06424002","phase":"PHASE4","title":"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-06-01","conditions":"Malaria,Falciparum","enrollment":5400},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT04666350","phase":"","title":"Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-09","conditions":"Malaria","enrollment":42},{"nctId":"NCT04041973","phase":"NA","title":"Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-03-11","conditions":"Malaria","enrollment":1480},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT02389374","phase":"PHASE4","title":"A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2014-08","conditions":"Malaria","enrollment":181},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT04767217","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study, Rwanda","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-06-14","conditions":"Uncomplicated Malaria","enrollment":528},{"nctId":"NCT04767191","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study (TES) Kenya","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-03-15","conditions":"Uncomplicated Malaria","enrollment":400},{"nctId":"NCT05958810","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2017-01-02","conditions":"Malaria,Falciparum, Malaria Recrudescence","enrollment":80},{"nctId":"NCT05958693","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2015","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2015-01-05","conditions":"Malaria,Falciparum, Malaria Recrudescence","enrollment":82},{"nctId":"NCT04222088","phase":"","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2013-05-01","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":159},{"nctId":"NCT04944966","phase":"PHASE2","title":"Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Ifakara Health Institute","startDate":"2021-06-02","conditions":"Malaria","enrollment":12},{"nctId":"NCT05095272","phase":"PHASE1","title":"Blood-Stage Plasmodium Vivax Cell Bank","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-02-15","conditions":"Malaria","enrollment":2},{"nctId":"NCT03813108","phase":"NA","title":"Safety and Efficacy of NF135 CPS Immunization","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2019-04-01","conditions":"Malaria,Falciparum, Controlled Human Malaria Infection, Immunization; Infection","enrollment":43},{"nctId":"NCT05874869","phase":"NA","title":"Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania","status":"COMPLETED","sponsor":"Richard Mwaiswelo","startDate":"2020-07-01","conditions":"Malaria, Chemoprophylaxis, Underfive Children","enrollment":13800},{"nctId":"NCT04147546","phase":"PHASE3","title":"Additional Screening With Sensitives RDTs and Malaria","status":"COMPLETED","sponsor":"Institut de Recherche en Sciences de la Sante, Burkina Faso","startDate":"2020-08-31","conditions":"Plasmodium Falciparum Malaria, Malaria Diagnosis","enrollment":340},{"nctId":"NCT03352843","phase":"PHASE4","title":"Single Low-dose Primaquine Efficacy and Safety.","status":"COMPLETED","sponsor":"Tropical Pesticides Research Institute, Tanzania","startDate":"2019-06-11","conditions":"Malaria","enrollment":157},{"nctId":"NCT04708496","phase":"PHASE4","title":"Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-01-18","conditions":"HIV Coinfection, Malaria","enrollment":888},{"nctId":"NCT05605925","phase":"PHASE4","title":"Ivermectin-artemisinin Combination Therapy for Eradication of Malaria","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2022-08-04","conditions":"Malaria","enrollment":138},{"nctId":"NCT03355664","phase":"PHASE3","title":"Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-19","conditions":"Malaria, Falciparum","enrollment":310},{"nctId":"NCT03952650","phase":"PHASE1, PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":"Malaria","enrollment":252},{"nctId":"NCT00495508","phase":"PHASE4","title":"Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy","status":"COMPLETED","sponsor":"Epicentre","startDate":"2006-10","conditions":"Malaria","enrollment":300},{"nctId":"NCT05340153","phase":"PHASE4","title":"Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2022-04-11","conditions":"Malaria","enrollment":184},{"nctId":"NCT04897919","phase":"PHASE4","title":"Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2015-08-01","conditions":"Malaria, Effectiveness","enrollment":474},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT04053907","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-08-15","conditions":"Malaria","enrollment":4000},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT03576313","phase":"PHASE3","title":"Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-11","conditions":"Malaria","enrollment":4939},{"nctId":"NCT03167242","phase":"PHASE2","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-02","conditions":"Acute Uncomplicated Plasmodium Falciparum Malaria","enrollment":524},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":"Malaria","enrollment":1117},{"nctId":"NCT05081089","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-12","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT03199755","phase":"PHASE2","title":"Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria","status":"WITHDRAWN","sponsor":"Worcester Polytechnic Institute","startDate":"2018-08-20","conditions":"Malaria","enrollment":""},{"nctId":"NCT03334747","phase":"PHASE2","title":"Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-16","conditions":"Malaria","enrollment":188},{"nctId":"NCT05070520","phase":"PHASE4","title":"Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites","status":"COMPLETED","sponsor":"Programme National de Lutte contre le Paludisme, Niger","startDate":"2020-09-01","conditions":"MALARIA","enrollment":259},{"nctId":"NCT05060198","phase":"NA","title":"Therapeutic Efficacy Study of AL and DP in Western Kenya","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2016-06-17","conditions":"Malaria,Falciparum","enrollment":340},{"nctId":"NCT03452475","phase":"PHASE3","title":"Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-07","conditions":"Plasmodium Falciparum","enrollment":219},{"nctId":"NCT04416945","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-09-20","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":31443},{"nctId":"NCT02315690","phase":"PHASE3","title":"Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-09","conditions":"Malaria","enrollment":4000},{"nctId":"NCT04310085","phase":"PHASE1","title":"Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-02-19","conditions":"Malaria,Falciparum, Parasitemia, Protozoan Infections","enrollment":16},{"nctId":"NCT03510481","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-14","conditions":"Malaria","enrollment":478},{"nctId":"NCT04456634","phase":"PHASE1","title":"Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2020-09-10","conditions":"Malaria","enrollment":8},{"nctId":"NCT00297882","phase":"PHASE3","title":"Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":"Malaria","enrollment":816},{"nctId":"NCT01133314","phase":"","title":"Artemether-Lumefantrine Effectiveness in Guinea-Bissau 2","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2010-05","conditions":"Malaria","enrollment":600},{"nctId":"NCT01704508","phase":"PHASE4","title":"Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2012-11","conditions":"Malaria","enrollment":346},{"nctId":"NCT01157689","phase":"","title":"Artemether-Lumefantrine Effectiveness in Guinea-Bissau","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2010-03","conditions":"Malaria","enrollment":500},{"nctId":"NCT04877626","phase":"PHASE4","title":"Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2008-09","conditions":"P. Falciparum Malaria","enrollment":210},{"nctId":"NCT04858087","phase":"","title":"Malawi International Center of Excellence in Malaria Research School-based Cohort","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-03-24","conditions":"Malaria, Malaria,Falciparum, Anemia","enrollment":786},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":"Falciparum Malaria","enrollment":184},{"nctId":"NCT04565184","phase":"PHASE4","title":"Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2019-05-09","conditions":"Malaria,Falciparum","enrollment":242},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT03783299","phase":"PHASE4","title":"Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-11-28","conditions":"Plasmodium Falciparum Malaria","enrollment":39968},{"nctId":"NCT02654912","phase":"PHASE4","title":"Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02","conditions":"Malaria","enrollment":8682},{"nctId":"NCT04094727","phase":"PHASE4","title":"Malaria High-Risk Populations in Namibia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-10-31","conditions":"Malaria","enrollment":3302},{"nctId":"NCT04531072","phase":"PHASE4","title":"Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine","status":"COMPLETED","sponsor":"Fogarty International Center of the National Institute of Health","startDate":"2018-09-18","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT02610400","phase":"PHASE3","title":"Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Malaria","enrollment":9845},{"nctId":"NCT04241705","phase":"NA","title":"Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia","status":"UNKNOWN","sponsor":"Armauer Hansen Research Institute, Ethiopia","startDate":"2020-01-20","conditions":"Malaria","enrollment":48960},{"nctId":"NCT00123552","phase":"PHASE3","title":"Longitudinal Antimalarial Combinations in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":"Malaria","enrollment":601}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1580,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(Riamet)","ARM-LUM","Mala1","Coartem"],"phase":"marketed","status":"active","brandName":"Artemether + Lumefantrine","genericName":"Artemether + Lumefantrine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (in combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}